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ABSTRACT
Objective. Epidermal growth factor receptor (EGFR)
and K-ras mutations guide treatment selection in non-
small cell lung cancer (NSCLC) patients. Although mu-
tation status is routinely assessed in biopsies, cytological
specimens are frequently the only samples available.
We determined EGFR and K-ras mutations in cytologi-
cal samples.
Methods. DNA was extracted from 150 consecutive
samples, including 120 Papanicolau smears (80%), 10 cell
blocks (7%), nine fresh samples (6%), six ThinPrep tests
(4%), and five body cavity fluids (3.3%). Papanicolau
smears were analyzed when they had >50% malignant
cells. Polymerase chain reaction and direct sequencing of
exons 18–21 of EGFR and exon 2 of K-ras were performed.
EGFR mutations were simultaneously determined in bi-
opsies and cytological samples from 20 patients. Activity of
EGFR tyrosine kinase inhibitors (TKIs) was assessed.
Results. The cytological diagnosis was adenocarcinoma
in 110 samples (73%) and nonadenocarcinoma in 40
(27%) samples. EGFR mutations were identified in 26
samples (17%) and K-ras mutations were identified in 18
(12%) samples. EGFR and K-ras mutations were mutually
exclusive. In EGFR-mutated cases, DNA was obtained
from stained smears in 24 cases (92%), pleural fluid in one
case (4%), and cell block in one case (4%). The response
rate to EGFR TKIs in patients harboring mutations was
75%. The mutation status was identical in patients who
had both biopsies and cytological samples analyzed.
Conclusion. Assessment of EGFR and K-ras muta-
tions in cytological samples is feasible and comparable
with biopsy results, making individualized treatment
selection possible for NSCLC patients from whom tu-
mor biopsies are not available. The Oncologist 2011;16:
877–885
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INTRODUCTION
Mutations in the tyrosine kinase (TK) domain of the epider-
mal growth factor receptor (EGFR) gene in non-small cell
lung cancer (NSCLC) patients are associated with clinical
response to the TK inhibitors (TKIs) gefitinib and erlotinib
[1–3]. These mutations are somatic and are more common
in patients with clinical features known to be associated
with sensitivity to TKIs, such as female gender, adenocar-
cinoma, Asian ethnicity. and lack of smoking history. The
discovery of these mutations and their clinical significance
has become a major step forward in the development of tar-
geted therapies with EGFR TKIs such as gefitinib and er-
lotinib [4–6].
Activating mutations within the TK domain of EGFR
are found in approximately 10%–20% of NSCLC pa-
tients and are associated with response to EGFR TKIs
[5, 6]. Gefitinib showed markedly better efficacy than
standard chemotherapy in this subset of patients [7, 8].
Deletions in exon 19 and the single L858R point muta-
tion in exon 21 account for 90% of all EGFR mutations
[1–3, 6]. These mutations mediate oncogenic effects by
altering downstream signaling and antiapoptotic mecha-
nisms [9] and are associated with clinical response and
survival following TKI therapy. Other genetic altera-
tions described in NSCLC, such as the T790M point mu-
tation or insertion mutations in exon 20 of EGFR,
amplification of MET, and mutations in K-ras, are asso-
ciated with a lack of activity of TKIs [10 –12]. As a re-
sult, assessment of mutation status has become part of the
standard management of NSCLC patients [6, 10].
Unfortunately, molecular testing is often hampered
by the inability to obtain appropriate tumor samples.
Currently, advanced lung cancer is frequently diagnosed
by fine-needle aspiration (FNA) performed via transbron-
chial needle aspiration (TBNA), endoscopic ultrasound
(EUS), or percutaneously, guided by computerized tomogra-
phy (CT) or echography [13–15]. The samples obtained are
often considered inadequate to yield sufficient material
to perform a complete molecular analysis [16, 17]. This
is particularly relevant in patients with advanced
NSCLC, in whom cytological specimens, often stained
smears, are frequently the only diagnostic material avail-
able, raising the question of whether or not more invasive
procedures should be performed [16]. We report our in-
stitution’s experience assessing EGFR and K-ras muta-
tions in tumor DNA extracted from cytological samples,
in particular from Papanicolau-stained slides. Clinical
outcomes of patients harboring mutations and their re-
sponse to TKI therapy are also discussed.
MATERIALS AND METHODS
Patients
Cytological samples from patients with suspected lung can-
cer were obtained consecutively at our institution by
TBNA, EUS, CT, ultrasound-guided FNA, or blind percu-
taneous FNA. Rapid onsite evaluation was performed by a
pathologist for all FNA procedures in order to guarantee
that samples were adequate. Stained smears received from
other hospitals for consultation and cytological samples ob-
tained from body cavity fluids were also analyzed. When
paraffin-embedded tumor biopsies were available, molecu-
lar analysis was performed and results were compared with
those obtained from cytological samples. The following
categories were used to define smoking status: smoker,
100 cigarettes per lifetime; nonsmoker, 100 cigarettes
per lifetime. An institutional review board–approved pro-
tocol allows biopsy specimens to be used for research pur-
poses. All patients signed informed consent before the
procedure.
DNA Extraction
A pathologist reviewed the Papanicolau-stained slides in
order to select the best slides for molecular analysis. The
criterion to select adequate slides was that they showed
50% malignant cells. Only one slide was used for DNA
extraction in each case. Prior to DNA extraction, Papa-
nicolau-stained smears were first rinsed in alcohol and
scraped into Eppendorf tubes. Slides were not destained
prior to DNA extraction. DNA was extracted using
Nucleospin Tissue (catalogue no., 740952.50; Mach-
erey-Nagel GmbH & Co. KG, Du¨ren, Germany). DNA
concentration was measured using a NanoDrop-1000
spectrophotometer (NanoDrop Technologies, Inc., Wil-
mington, DE).
EGFR and K-ras Mutation Analysis
Polymerase chain reaction (PCR) and direct sequencing of
exons 18–21 of EGFR and exon 2 of K-ras were performed
using an ABI Prism™ 310XL DNA sequencer (Applied
Biosystems, Madrid, Spain). The primer sequences used,
cycling conditions, and annealing temperatures of touch-
down PCR for EGFR analysis are shown in Table 1. The
presence of an appropriate PCR product was confirmed by
resolving the PCR products on a 2% agarose gel. PCR prod-
ucts were purified using the GFX™ PCR DNA and Gel
Band Purification kit (GE Healthcare Bio-Sciences AB,
Bjo¨rkgatan, Sweden) following the manufacturer’s instruc-
tions. Fragments were sequenced and analyzed in both the
sense and antisense directions. DNA templates were pro-
cessed for the DNA sequencing reaction using ABI
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Prism™ BigDye Terminator, version 3.1 (Applied Biosys-
tems).
Following sequencing reactions, DNA was purified us-
ing Performa DTR Gel Filtration Cartridges (EdgeBio,
Gaithersburg, MD). Sequence data were generated with the
ABI Prism 310 DNA analyzer (Applied Biosystems). Mu-
tations were identified by visual analysis of the sequenced
chromatograms using SeqScape (Applied Biosystems). Se-
quence data were analyzed by two investigators and com-
pared with the archived human sequence of EGFR
(GenBank accession no., NG_007726.1; K-ras GenBank
accession no., NG_007524.1).
Clinical Assessment and Statistical Analysis
The response rate of patients treated with TKIs was as-
sessed using Response Evaluation Criteria in Solid Tumors
[18]. The progression-free survival (PFS) interval was cal-
culated from the date when treatment with the TKI was
started to the date of progression or death from any cause.
Descriptive statistics are used to present patient character-
istics and results of the molecular analysis. Statistical com-
parisons were performed using Fisher’s exact test. Survival
data were analyzed using the Kaplan–Meier method [19].
Statistical analyses were performed using SPSS software
(SPSS Inc., Chicago, IL). Agreement between the mutation
status assessed in cytological samples and in biopsies was
assessed using Cohen’s  coefficient [20]. The relationship
between the  coefficient and strength of between-method
agreement may be interpreted in the following manner:
0.81–1.00, almost perfect; 0.61– 0.80, substantial; 0.41–
0.60, moderate; 0.21–0.40, fair; 0–0.20, slight; and 0,
poor [21].
RESULTS
Patients and Tumor Samples
Between January 2007 and December 2009, 150 cytologi-
cal samples from NSCLC patients were consecutively ob-
tained and analyzed. Patient characteristics, tumor
histology, and DNA source are shown in Table 2. Samples
were obtained from FNA of primary lung tumors in 68
cases (45.3%), metastatic lymph nodes in 70 cases (46.6%),
bone metastases in three cases (2%), a left adrenal metasta-
sis in one case (0.7%), pleural fluid in six cases (4%), peri-
cardial fluid in one case (0.7%), and bronchoalveolar
lavage in one case (0.7%). TBNA was the diagnostic pro-
cedure in 104 patients, whereas EUS-FNA was used in five
patients, CT-guided percutaneous FNA was used in 10 pa-
tients, and ultrasound-guided percutaneous FNA was used
in three patients. In 11 patients, the pathologist performed
an FNA directly on superficial lymph nodes. In eight pa-
tients, the samples were stained smears received from other
hospitals for consultation, obtained by FNA from lymph
nodes (six mediastinal, through TBNA, and two superficial,
by direct FNA). Six samples originated from body cavity
fluids, and three resulted from bronchial biopsy touch
preps. DNA was extracted from 120 Papanicolau-stained
smears (80%), 10 cell blocks (6.7%), nine fresh samples
(6%), six ThinPrep tests (4%), and five body cavity fluids
(3.3%). DNA was successfully extracted from all samples
studied. We obtained an average of 24.6 ng/l (standard de-
viation, 15.3) of DNA.
The majority of the lesions were diagnosed as adenocar-
cinoma (n 110; 73.3%) Twenty-seven patients (18%) had
Table 1. Primer sequences and cycling conditions for touchdown PCR
Exon Primers AT PCR conditions
EGFR 18 Forward, 5-CAAGTGCCGTGTCCTGGCACCCAAGC-3 AT1, 64°C Step 1: 95°C, 10 minutes
Reverse, 5-CCAAACACTCAGTGAAACAAAGAG-3 AT2, 57°C Step 2: 95°C, 30 seconds
EGFR 19 Forward, 5-GTGCATCGCTGGTAACATCC-3 AT1, 64°C Step 3: AT1 decreases 0.5°C
per cycle, 30 seconds
Reverse, 5-TGTGGAGATGAGCAGGGTCT-3 AT2, 57°C Step 4: 72°C, 30.0 seconds
EGFR 20 Forward, 5-ATCGCATTCATGCGTCTTCA-3 AT1, 60.2°C Step 5: Repeat steps 2–4 14
more times
Reverse, 5-ATCCCCATGGCAAACTCTTG-3 AT2, 53.2°C Step 6: 95°C, 30 seconds
EGFR 21 Forward, 5-GCTCAGAGCCTGGCATGAA-3 AT1, 64°C Step 7: AT2, 30 seconds
Reverse, 5-CATCCTCCCCTGCATGTGT-3 AT2, 57°C Step 8: 72°C, 30.0 seconds
Step 9: Repeat steps 6–8 19
more times
K-ras 2 Forward, 5-GGTGGAGTATTTGATAGTGTA-3 AT1, 57°C Step 10: 72°C, 10 minutes
Reverse, 5-GGTCCTGCACCAGTAATATGC-3 AT2, 50°C Step 11: 4°C, forever
Abbreviations: AT, annealing temperature; EGFR, epidermal growth factor receptor; PCR, polymerase chain reaction.
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squamous cell carcinoma, four (2.7%) had large cell carci-
noma, and nine (6%) had poorly differentiated NSCLC.
EGFR Mutation Status
We identified 26 EGFR mutations in the 150 samples ana-
lyzed. The frequency of EGFR mutations, patient charac-
teristics, tumor type, and source of DNA for mutational
analysis are shown in Table 2. All 26 mutations were de-
scribed in adenocarcinomas. From the 26 mutations de-
tected, 24 were identified in DNA from Papanicolau-
stained smears. Mutations were found in 20 of 62 women
(32.3%) and in six of 88 men (6.8%). EGFR mutations were
identified in 17 of 40 nonsmokers (42.5%), but in only nine
of 110 smokers (8.2%) (p .001) (Table 2). A representa-
tive case is presented in Figure 1.
Table 3 summarizes all EGFR mutations detected as
well as the characteristics of the patients and the sampling
technique used. We found 18 mutations (69.2%) in exon 19,
six mutations (23%) in exon 21, one mutation (3.8%) in
exon 20, and one mutation (3.8%) in exon 18. In exon 19 we
found 11 deletions (42.3%), one missense mutation (3.8%),
five deletion plus missense mutations (19.2%), and one de-
letion plus insertion (3.8%). Exon 20 had an insertion, and
in exon 21, all six alterations were missense mutations.
Paraffin-embedded tissue was available from 20 pa-
tients. Analysis of EGFR mutation status in those samples
revealed agreement with the results obtained in cytological
samples in every case (1.0 or perfect agreement, as assessed
by the  coefficient).
K-ras Mutation Status
K-ras mutation status was assessed in 111 cases. Table 4
shows K-ras mutation types, diagnosis, and patient charac-
teristics. We found K-ras mutations in 18 patients (12%).
K-ras and EGFR mutations were mutually exclusive. Mu-
tations in K-ras were observed in DNA extracted from Pa-
panicolau-stained smears in 16 cases (89%), and from
ThinPrep tests in two cases (11%).
Clinical Activity of TKIs
Clinical follow-up was available for 16 of the 26 patients
with EGFR mutations who presented with stage IV disease.
Based on the identification of such mutations, these patients
received subsequent therapy with a TKI, including erlotinib
[14] and gefitinib [2]. EGFR TKIs were administered as
first-line therapy in eight patients (50%), as second-line
therapy in seven patients (44%), and as fifth-line therapy in
one patient (6%). We observed one complete response and
11 partial responses (overall response rate, 75%). In addi-
tion, one patient showed a minor response and two had on-
going stable disease at 15 and 20 months. One patient
presented rapid progression at the first evaluation of dis-
ease. The median PFS duration of patients with EGFR mu-
Table 2. Patient characteristics, frequency of mutations, type of tumor, and source of DNA for mutational analysis
Characteristic
All cases EGFR mutations K-ras mutations
n 150 (%) n 26 (%) n 18 (%)
Gender
Female 62 (41.3) 20 (76.9) 6 (33.3)
Male 88 (58.7) 6 (23.1) 12 (66.7)
Smoking
Yes 110 (73.3) 9 (34.6) 18 (100)
No 40 (26.7) 17 (65.4) 0
Tumor type
Adenocarcinoma 110 (73.3) 26 (100) 13 (72.2)
Squamous 27 (18) 0 1 (5.5)
Large cell 4 (2.7) 0 2 (11.1)
Poorly differentiated NSCLC 9 (6) 0 2 (11.1)
DNA source
Stained slides 120 (80) 24 (92.4) 16 (88.9)
Fresh/liquid 14 (9.3) 1 (liquid) (3.8) 0
Cell block 10 (6.7) 1 (3.8) 0
ThinPrep 6 (4) 0 2 (11.1)
Abbreviations: EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer.
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tations who were treated with erlotinib or gefitinib was 12.3
months (Fig. 2).
DISCUSSION
Molecular profiling is now considered the standard of care
for patients with NSCLC [5, 6, 22]. The development of tar-
geted therapies against the EGFR TK domain has led to the
discovery of mutations and other genomic alterations that
predict the efficacy of these agents. Paraffin-embedded and
frozen tissue have been considered optimal samples for mo-
lecular studies. Consequently, most reports published on
EGFR analyses were performed using biopsies. However, bi-
opsies are not always available, because the diagnosis of lung
cancer sometimes relies on cytological samples obtained by
FNA through minimally invasive procedures in order to avoid
more invasive techniques [13–15]. Therefore, the possibility
of performing molecular analyses on samples obtained using
minimally invasive procedures is appealing [23]. To our
knowledge, our study is the first large series to show that Pa-
panicolau-stained cytological samples are adequate for EGFR
and K-ras mutation analysis. We believe this technique could
be introduced into clinical practice.
Figure 1. Representative example of a case included in our series. (A): Papanicolau-stained smear showing lung adenocarcinoma
cells obtained by fine-needle aspiration from a supraclavicular lymph node. (B): Direct sequencing of exon 19 showing a deletion
and a point mutation (del L747–E749, A750P).
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The prior literature on EGFR mutation analysis relies
primarily on larger tumor biopsies, but our results are com-
parable with regard to the frequency and distribution of
EGFR mutations according to sex, histology, and prior
smoking history, as well EGFR TKI activity [1–3, 6]. The
75% response rate and the median PFS interval of 12.3
months compare favorably with the 70.6% response rate
and 14-month PFS interval reported in one of the most rel-
evant series published to date [6]. Moreover, mutation sta-
tus was determined in cytology as well as in biopsy samples
in a subgroup of patients, and the agreement between the
two methods was perfect. EGFR mutations were never ob-
served in patients who had K-ras mutations, as has previ-
ously been reported [22].
Currently, there is ongoing debate in the oncologic com-
munity regarding the adequacy of samples obtained for mo-
lecular analysis from NSCLC patients. Although initial
data suggested that cytological samples were not adequate
for molecular analysis [16], recent findings suggest that
minimally invasive techniques might suffice [10]. Some
studies have evaluated the feasibility of assessing EGFR
mutation status in paraffin-embedded cell blocks and histo-
logical cores from NSCLC patients obtained by TBNA and
FNA [24–26]. Smouse et al. [27] recently showed that cy-
tological cell blocks provide equivalent, if not higher, sen-
sitivity when compared with surgical specimens,
suggesting that the suitability of a sample should be based
on tumor cell proportion and abundance, rather than on the
technique used to obtain the sample. We agree with this
concept, and we believe that the quality of the sample is a
Table 3. Characteristics of patients with EGFR mutations
Patient EGFR mutation Exon Sex Age
Sampling
technique Diagnosis Smoking
DNA
source
1 E709K, G719A 18 F 83 BC-FNA AC (BAC) No SS
2 del E746-A750 19 F 53 BC-FNA AC No SS
3 del E746-A750 19 F 60 Thoracocentesis AC Yes Pleural fluid
4 del E746-A750 19 F 64 BC-FNA AC Yes SS
5 del E746-A750 19 F 65 BC-FNA AC No SS
6 del E746-A750 19 F 74 CT-FNA AC No SS
7 del E746-A750 19 M 47 Direct FNA AC Yes SS
8 del E746-A750 19 M 65 BC-FNA AC Yes SS
9 del E746-A750 19 M 70 BC-FNA AC No SS
10 del E746-A750 19 M 72 BC-FNA AC No SS
11 del E746-A750 19 M 75 BC-FNA AC No SS
12 del E746-A750 19 M 76 Consultationa AC No SS
13 del747-T751, K754E 19 F 47 BC-FNA AC Yes SS
14 delL747-E749, A750P 19 F 48 BC-FNA AC Yes SS
15 delL747-E749, A750P 19 F 61 BC-FNA AC No SS
16 delL747-T751insS 19 F 67 BC-FNA AC No SS
17 delL747-E749, A750P 19 F 72 Direct FNA AC No SS
18 delL747-E749, A750P 19 F 72 Direct FNA AC No SS
19 L747P 19 F 60 BC-FNA AC Yes SS
20 N771insH 20 F 61 BC-FNA AC Yes SS
21 L858R 21 F 47 EUS-FNA AC Yes SS
22 L858R 21 F 60 Direct FNA AC No SS
23 L858R 21 F 60 BC-FNA AC No SS
24 L858R 21 F 72 BC-FNA AC No SS
25 L858R 21 F 82 BC-FNA AC No SS
26 L858R 21 F 87 BC-FNA AC No Cell block
aStained slides received for consultation.
Abbreviations: AC, adenocarcinoma; BAC, bronchioloalveolar carcinoma; BC-FNA, bronchoscopy-guided FNA; CT-FNA,
CT scan–guided FNA; EUS-FNA, endoscopic ultrasound–guided FNA; F, female; FNA, fine-needle aspiration; M, male;
SS, stained smear.
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Table 4. Summary of K-ras mutation types, histological diagnosis, and patient characteristics
Patient Sex Age
K-ras
mutation
Sampling
technique Diagnosis
Smoking
status
DNA
source
1 F 54 G12D BC-FNA AC Yes SS
2 M 61 G12D BC-FNA AC Yes SS
3 M 43 G12D BC-FNA SqCC Yes SS
4 M 59 G12C Imprints AC Yes SS
5 M 66 G12V BC-FNA AC Yes ThinPrep
6 F 49 G13D EUS-FNA AC Yes SS
7 F 41 G12C BC-FNA AC Yes SS
8 M 55 G12F CT-FNA AC Yes SS
9 M 45 G12C BC-FNA AC Yes SS
10 M 62 G13C BC-FNA NSCLC Yes SS
11 M 59 G12D BC-FNA NSCLC Yes SS
12 F 68 G12V IO-FNA AC Yes SS
13 F 70 G12V BC-FNA AC Yes SS
14 M 82 G12A BC-FNA LCC Yes ThinPrep
15 F 67 G12C BC-FNA LCC Yes SS
16 M 68 G12V Imprints AC Yes SS
17 M 55 L19F BC-FNA AC Yes SS
18 M 67 G12C BC-FNA AC Yes SS
Abbreviations: AC, adenocarcinoma; BC-FNA, bronchoscopy-guided FNA; CT-FNA, CT scan–guided FNA; EUS-FNA,
endoscopic ultrasound–guided FNA; F, female; FNA, fine-needle aspiration; IO-FNA, intraoperative FNA; LCC, large cell
carcinoma; M, male; NSCLC, non-small cell lung cancer; SqCC, squamous cell carcinoma; SS, stained smear.
Figure 2. Progression-free survival of patients presenting with epidermal growth factor receptor gene mutations treated with
erlotinib and gefitinib.
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critical factor in order to obtain adequate results. In our
study, we assessed mutations only from slides that con-
tained 50% malignant cells.
To our knowledge, this is the largest series analyzing
EGFR mutations in exons 18–21 as well as K-ras mutations
in cytological samples. Molecular analysis results were val-
idated with clinical outcomes as well as simultaneous as-
sessment using traditional biopsy samples. A few small
series have assessed mutations in exons 19 and 21 of EGFR
using cytological samples, some of them including Papani-
colau-stained smears. Boldrini et al. [28] reported their ret-
rospective results from a small series of 23 cytological
samples. Nomoto et al. [29] and Smith et al. [30] analyzed
the feasibility of a high-resolution melting analysis to per-
form EGFR mutational analysis in small specimens, includ-
ing cytological samples. Fukui et al. [31] reported their
results with small diagnostic samples and biopsies from 92
patients. They reported better results from PCR analysis us-
ing cytological slides rather than biopsy specimens, regard-
less of the amount of tumor cells analyzed. They explained
this fact by differences in the method of sample fixation be-
tween the two types of specimens, favoring methanol over
formalin for mutational studies, thus highlighting the im-
portance of preserving high-quality DNA. Savic et al. [32]
studied the presence of EGFR mutations in NSCLC sam-
ples, including some Papanicolau-stained slides from
NSCLC patients, using sequencing methods. None of the
previous studies provided clinical information on the out-
come of the patients treated with TKIs to confirm their pre-
dictive value. Oshita et al. [33] evaluated a novel
heteroduplex method to study some of the most frequently
described mutations in exons 19 and 21 of EGFR in cytol-
ogy specimens obtained by transbronchial abrasion from 52
NSCLC patients. They assessed the clinical activity of ge-
fitinib in 26 patients, reporting a 91% response rate in the 11
patients that had mutations. Our study added a determina-
tion of the concordance between mutation assessment in bi-
opsies and in cytological samples.
The main limitation of our study is the limited sample
size. Although we showed that assessment of mutations in
cytological samples is feasible, further studies are neces-
sary to determine the specificity and sensitivity of this tech-
nique. In addition, this methodology, as any other, requires
a learning curve during which simultaneous assessment of
mutations in paraffin samples, if available, can provide
quality control.
CONCLUSION
Our results show that assessment of EGFR mutations in ex-
ons 18–21 and K-ras mutation status in cytological sam-
ples, including Papanicolau-stained slides, from NSCLC
patients is feasible and results are comparable with those
obtained from biopsies. Identification of EGFR mutations
in cytological samples predicts clinical response to targeted
therapies, thus extending the benefits of individualized
treatment selection to NSCLC patients from whom tumor
biopsies are not available. This finding may facilitate large-
scale screening of patients with NSCLC for EGFR muta-
tions with minimally invasive techniques, avoiding more
invasive procedures. In addition, this strategy can be used
for research purposes.
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